Alnylam Pharmaceuticals (ALNY) Total Current Liabilities (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Total Current Liabilities data on file, last reported at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 25.46% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 25.46% YoY), and the FY2025 full-year result was $1.5 billion, up 23.61% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $1.3 billion, down from $1.5 billion in the prior quarter.
• Across five years, Total Current Liabilities topped out at $1.6 billion in Q3 2025 and bottomed at $606.0 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $967.8 million (2023), against an average of $1.0 billion.
• The widest annual swing landed in 2022, when Total Current Liabilities climbed 10.38%; it then surged 39.85% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $767.9 million in 2022, then rose by 26.03% to $967.8 million in 2023, then gained by 22.58% to $1.2 billion in 2024, then rose by 23.61% to $1.5 billion in 2025, then slipped by 7.97% to $1.3 billion in 2026.
• The last three Total Current Liabilities figures came in at $1.3 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.

Peer Comparison